WS02.12 Aumolertinib Plus Anlotinib as 1st-Line Treatment for EGFR Mutant Non-Small Cell Lung Cancer: A Phase II Trial (ALWAYS)

• DOI: 10.1016/j.jtho.2023.09.012
• Publication Date: 2023-10-31T05:23:18Z
• Authors: H.l. Chen; T.t. Xia; G.b. Huang; H.y. Ye; Y.p. Luo; H.g. Chen; M.l. Liu; S.j. Li; Z.x. Yang
• Keywords: Line (geometry)